JP2006511196A5 - - Google Patents

Download PDF

Info

Publication number
JP2006511196A5
JP2006511196A5 JP2004509714A JP2004509714A JP2006511196A5 JP 2006511196 A5 JP2006511196 A5 JP 2006511196A5 JP 2004509714 A JP2004509714 A JP 2004509714A JP 2004509714 A JP2004509714 A JP 2004509714A JP 2006511196 A5 JP2006511196 A5 JP 2006511196A5
Authority
JP
Japan
Prior art keywords
peptide
presenting cell
antigen presenting
mutation
bound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004509714A
Other languages
English (en)
Japanese (ja)
Other versions
JP4472520B2 (ja
JP2006511196A (ja
Filing date
Publication date
Priority claimed from DE10225144A external-priority patent/DE10225144A1/de
Application filed filed Critical
Publication of JP2006511196A publication Critical patent/JP2006511196A/ja
Publication of JP2006511196A5 publication Critical patent/JP2006511196A5/ja
Application granted granted Critical
Publication of JP4472520B2 publication Critical patent/JP4472520B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004509714A 2002-05-29 2003-03-27 Ｍｈｃ分子に結合する腫瘍関連ペプチド Expired - Fee Related JP4472520B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10225144A DE10225144A1 (de) 2002-05-29 2002-05-29 An MHC-Moleküle bindende Tumor-assoziierte Peptide
PCT/EP2003/003181 WO2003102023A1 (de) 2002-05-29 2003-03-27 An mhc-moleküle bindende tumor-assoziierte peptide

Related Child Applications (4)

Application Number Title Priority Date Filing Date
JP2009283584A Division JP5042301B2 (ja) 2002-05-29 2009-12-15 Ｍｈｃ分子に結合する腫瘍関連ペプチド
JP2009283583A Division JP5042300B2 (ja) 2002-05-29 2009-12-15 Ｍｈｃ分子に結合する腫瘍関連ペプチド
JP2009283586A Division JP5042303B2 (ja) 2002-05-29 2009-12-15 Ｍｈｃ分子に結合する腫瘍関連ペプチド
JP2009283585A Division JP5042302B2 (ja) 2002-05-29 2009-12-15 Ｍｈｃ分子に結合する腫瘍関連ペプチド

Publications (3)

Publication Number Publication Date
JP2006511196A JP2006511196A (ja) 2006-04-06
JP2006511196A5 true JP2006511196A5 (https=) 2009-09-03
JP4472520B2 JP4472520B2 (ja) 2010-06-02

Family

ID=29557592

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2004509714A Expired - Fee Related JP4472520B2 (ja) 2002-05-29 2003-03-27 Ｍｈｃ分子に結合する腫瘍関連ペプチド
JP2009283584A Expired - Fee Related JP5042301B2 (ja) 2002-05-29 2009-12-15 Ｍｈｃ分子に結合する腫瘍関連ペプチド
JP2009283586A Expired - Fee Related JP5042303B2 (ja) 2002-05-29 2009-12-15 Ｍｈｃ分子に結合する腫瘍関連ペプチド
JP2009283585A Expired - Fee Related JP5042302B2 (ja) 2002-05-29 2009-12-15 Ｍｈｃ分子に結合する腫瘍関連ペプチド
JP2009283583A Expired - Fee Related JP5042300B2 (ja) 2002-05-29 2009-12-15 Ｍｈｃ分子に結合する腫瘍関連ペプチド

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2009283584A Expired - Fee Related JP5042301B2 (ja) 2002-05-29 2009-12-15 Ｍｈｃ分子に結合する腫瘍関連ペプチド
JP2009283586A Expired - Fee Related JP5042303B2 (ja) 2002-05-29 2009-12-15 Ｍｈｃ分子に結合する腫瘍関連ペプチド
JP2009283585A Expired - Fee Related JP5042302B2 (ja) 2002-05-29 2009-12-15 Ｍｈｃ分子に結合する腫瘍関連ペプチド
JP2009283583A Expired - Fee Related JP5042300B2 (ja) 2002-05-29 2009-12-15 Ｍｈｃ分子に結合する腫瘍関連ペプチド

Country Status (15)

Country Link
US (5) US7396904B2 (https=)
EP (5) EP1734048B1 (https=)
JP (5) JP4472520B2 (https=)
AT (5) ATE466872T1 (https=)
AU (2) AU2003224001B2 (https=)
CA (5) CA2736972C (https=)
CY (5) CY1108507T1 (https=)
DE (6) DE10225144A1 (https=)
DK (5) DK1734048T3 (https=)
ES (5) ES2317379T3 (https=)
HR (1) HRP20041108B1 (https=)
PL (5) PL206306B1 (https=)
PT (5) PT1507795E (https=)
SI (5) SI1734049T1 (https=)
WO (1) WO2003102023A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US20050221350A1 (en) 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
DE10225139A1 (de) * 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
US7670604B2 (en) 2002-12-13 2010-03-02 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
ES2633389T3 (es) * 2003-01-30 2017-09-21 Survac Aps Péptidos derivados de survivina y uso de los mismos
DE10313819A1 (de) * 2003-03-24 2004-10-07 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
ATE458747T1 (de) * 2003-12-01 2010-03-15 Meiji Dairies Corp Angiontensin converting enzyme hemmendes peptid
JP2007515924A (ja) * 2003-12-15 2007-06-21 アウレリウム バイオファーマ インク． ビメンチン指向性診断法、および、多剤耐性を示す腫瘍性疾患の治療法
DE102004011503A1 (de) * 2004-01-28 2005-09-15 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung und Quantifizierung von tumor-assoziierten Peptiden
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
PL1642905T3 (pl) * 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
PL2565204T3 (pl) 2007-07-27 2016-03-31 Immatics Biotechnologies Gmbh Nowe immunogenne epitopy do immunoterapii
WO2009129498A2 (en) * 2008-04-17 2009-10-22 Immuneregen Biosciences, Inc. Substance p and analogs thereof as a cancer immunogenic composition adjuvant
SI2119726T2 (en) 2008-05-14 2018-03-30 Immatics Biotechnologies Gmbh New and powerful Class II MHC peptides derived from survivin and neurocane
CN101451975B (zh) * 2008-12-29 2012-01-25 浙江大学 一种检测胃癌预后与分期血清蛋白质的方法
US8075895B2 (en) * 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
US9555074B2 (en) 2010-10-08 2017-01-31 Regents Of The University Of Minnesota Annexin II compositions
PL3456339T3 (pl) * 2013-08-05 2022-03-21 Immatics Biotechnologies Gmbh Nowa immunoterapia przeciwko szeregu nowotworom, takim jak rak płuc, w tym nsclc
US20160310583A1 (en) * 2013-10-03 2016-10-27 Sumitomo Dainippon Pharma Co., Ltd. Tumor antigen peptide
ES2928331T3 (es) 2013-11-13 2022-11-17 Univ Minnesota Composiciones de variantes de anexina II y métodos
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
ES2983924T3 (es) 2015-03-27 2024-10-28 Immatics Biotechnologies Gmbh Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
CN108026154B (zh) 2015-07-01 2022-03-08 伊玛提克斯生物技术有限公司 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520558D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201521746D0 (en) 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
HRP20210698T1 (hr) 2015-12-22 2021-09-17 Immatics Biotechnologies Gmbh Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma
DE102016005550B4 (de) 2016-05-09 2024-09-26 Hans-Georg Rammensee Adjuvans zur lnduzierung einer zellulären lmmunantwort
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
KR102184377B1 (ko) 2018-02-19 2020-11-30 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
WO2019160383A1 (ko) * 2018-02-19 2019-08-22 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
BR102018010523A2 (pt) * 2018-05-23 2020-04-28 Univ Estadual Campinas Unicamp peptídeo, composição farmacêutica compreendendo o mesmo e uso

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810781A (en) * 1987-01-15 1989-03-07 The George Washington University Methods of preparing epitopes of tumor associated antigens
US5739009A (en) * 1996-12-12 1998-04-14 Incyte Pharmaceuticals, Inc. Adipocyte-specific differentiation-related protein
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
DE19837015C2 (de) * 1998-08-14 2003-03-20 Vasopharm Biotech Gmbh Isolierte und gereinigte humane lösliche Guanylylcyclase alpha1/beta1 (hsGCalpha1/beta1)
US6809179B1 (en) 1999-08-04 2004-10-26 Boehringer Ingelheim International Gmbh Tumor-associated antigen (R11)
DE19936563A1 (de) 1999-08-04 2001-02-08 Boehringer Ingelheim Int Tumorassoziiertes Antigen
WO2001062787A1 (en) * 2000-02-24 2001-08-30 Oxford Glycosciences (Uk) Limited Diagnosis and treatment of bipolar affective disorder
WO2002050103A2 (en) * 2000-12-20 2002-06-27 Glaxosmithkline Biologicals S.A. Tumour-related antigens
US20030170719A1 (en) * 2000-12-28 2003-09-11 Akio Matsuda NF-kappa B activating gene
CA2444691A1 (en) * 2001-04-18 2002-10-31 Protein Design Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US7125663B2 (en) * 2001-06-13 2006-10-24 Millenium Pharmaceuticals, Inc. Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2003048323A2 (en) * 2001-12-03 2003-06-12 Bristol-Myers Squibb Company Polynucleotides and polypeptides associated with the development of rheumatoid arthritis

Similar Documents

Publication Publication Date Title
JP2006511196A5 (https=)
JP2004517472A5 (https=)
EP2481422A3 (en) Multiplex vaccines
JP2004502858A5 (https=)
EP2246067A3 (en) Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
JP2007515393A5 (https=)
JPH11302527A5 (https=)
JP2005520490A5 (https=)
BR0010711A (pt) Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes
WO2003005880A3 (en) Replikin peptides and uses thereof
JP2006502943A5 (https=)
DE69515340D1 (de) Impfstoff gegen mycobakterielle infektionen
JP2004503217A5 (https=)
JP2005154531A5 (https=)
JP2006515744A5 (https=)
BR9800606A (pt) Seção de recheio , e , leito
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
EP2583981A3 (en) Antibodies and related molecules that bind to PSCA proteins
CA2529001A1 (en) Binding peptides: methods for their generation and use
JP2005515282A5 (https=)
JP2008546803A5 (https=)
JP2002518346A5 (https=)
JP2004519453A5 (https=)
JP2005005118A5 (https=)
JP2005535635A5 (https=)